| Effect | None |
| Trial Design | Double blind |
| Trial Length | 6+ Months |
| Number of Subjects | 30 |
| Gender | Both Genders |
| Age Range | 7-12, 13-17, 18-29, 30-44 |
DSM 17938 at 10^8^ CFU daily for six months noted that, in a double blind crossover design, that persons with cystic firbosis experienced a betterment of intestinal discomfort associated with beneficial changes in the gut microflora (which is inherently altered from the norm in cystic fibrosis). Despite benefits to intestinal discomfort, no overall changes were noted on the SF-12 (general health survey).
Lung power and inflammatory/antiinflammatory cytokines were all unaffected, although fecal calprotectin (biomarker of intestinal inflammation) was reduced by 40%.
Lactobacillus Reuteri ATCC55730 In Cystic Fibrosis
| Effect | None |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 60 |
| Gender | Both Genders |
| Age Range | 13-17, 18-29 |
Supplementation of 10^10^ CFU _L. reuteri_ ATCC 55730 in persons with cystic fibrosis failed to alter pulmonary capacity or sputum (symptoms of cystic fibrosis) relative to placebo, although the amount of pulmonary exacerbations seen during supplemetnation was greatly reduced from 11 events in placebo (out of 30 persons) down to a lone event with supplementation.
Risk of upper respiratory tract infection was also significantly reduced in these persons, with no alterations in gastrointestinal tract infection risk.